HOXC10在消化系统肿瘤中的研究进展

doi:10.3760/cma.j.cn371439-20250704-00134

国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (12): 787-790.doi: 10.3760/cma.j.cn371439-20250704-00134

HOXC10在消化系统肿瘤中的研究进展

宋雪琴, 李明英()

西南医科大学附属医院医学实验中心，泸州 646000

收稿日期:2025-07-04 修回日期:2025-08-10 出版日期:2025-12-08 发布日期:2025-12-31
通讯作者: 李明英 E-mail:limingying2005@126.com
基金资助:
泸州市科技计划(2024JYJ046);西南医科大学自然科学青年项目(2022QN028);西南医科大学自然科学青年项目(2022QN107)

Research progress of HOXC10 in digestive system neoplasms

Song Xueqin, Li Mingying()

Experimental Medicine Center，Affiliated Hospital of Southwest Medical University，Luzhou 646000，China

Received:2025-07-04 Revised:2025-08-10 Online:2025-12-08 Published:2025-12-31
Contact: Li Mingying E-mail:limingying2005@126.com
Supported by:
Science and Technology Plan Project of Luzhou of China(2024JYJ046);Natural Science Youth Program of Southwest Medical University(2022QN028);Natural Science Youth Program of Southwest Medical University(2022QN107)

摘要/Abstract

摘要：

HOXC10是一种同源盒基因，其与消化系统肿瘤的发生发展密切相关。在食管癌、胃癌、肝癌、结直肠癌中，HOXC10的表达呈不同程度的升高，与肿瘤细胞增殖、转移侵袭、凋亡、耐药等生物学过程密切相关，其通过多种途径参与肿瘤调控，发挥促癌作用，影响患者预后。HOXC10有望成为消化系统肿瘤潜在的分子靶点。

关键词: 消化系统肿瘤, 基因表达, 致癌作用, HOXC10

Abstract:

HOXC10 is a homeobox gene that is closely related to the occurrence and development of digestive system neoplasms. In esophageal cancer， gastric cancer， liver cancer and colorectal cancer， the expression of HOXC10 shows varying degrees of increase， which is closely related to the biological processes such as tumor cell proliferation， metastasis and invasion， apoptosis， and drug resistance， and it participates in tumor regulation through various pathways， which exerts a carcinogenic effect and affects the prognosis of patients. HOXC10 is expected to be a potential molecular target for digestive system neoplasms.

Key words: Digestive system neoplasms, Gene expression, Carcinogenesis, HOXC10

宋雪琴, 李明英. HOXC10在消化系统肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(12): 787-790.

Song Xueqin, Li Mingying. Research progress of HOXC10 in digestive system neoplasms[J]. Journal of International Oncology, 2025, 52(12): 787-790.

参考文献 28

[1]	Zhan T, Betge J, Schulte N, et al. Digestive cancers: mechanisms, therapeutics and management[J]. Signal Transduct Target Ther, 2025, 10(1): 24. DOI: 10.1038/s41392-024-02097-4.
[2]	Wu Y, He S, Cao M, et al. Comparative analysis of cancer statistics in China and the United States in 2024[J]. Chin Med J (Engl), 2024, 137(24): 3093-3100. DOI: 10.1097/CM9.0000000000003442.
[3]	赵倩雯, 彭丹莉, 秦韬, 等. 1990—2019年全球肿瘤发病死亡分析[J]. 国际肿瘤学杂志, 2023, 50(7): 425-431. DOI: 10.3760/cma.j.cn371439-20230315-00082.
[4]	Song H, Hao Y, Xie Q, et al. HOXC10-mediated 'positional memory' regulates cartilage formation subsequent to femoral heterotopic grafting[J]. J Cell Mol Med, 2024, 28(20): e70140. DOI: 10.1111/jcmm.70140.
[5]	Tan HYA, Sim MFM, Tan SX, et al. HOXC10 suppresses browning to maintain white adipocyte identity[J]. Diabetes, 2021, 70(8): 1654-1663. DOI: 10.2337/db21-0114. pmid: 33990396
[6]	Fang J, Wang J, Yu L, et al. Role of HOXC10 in cancer[J]. Front Oncol, 2021, 11: 684021. DOI: 10.3389/fonc.2021.684021.
[7]	Gomes JV, Nicolau-Neto P, de Almeida JN, et al. HOXA7 expression is an independent prognostic biomarker in esophageal squamous cell carcinoma[J]. Genes (Basel), 2024, 15(11): 1430. DOI: 10.3390/genes15111430.
[8]	He X, Wang H, Wang R, et al. HOXC10 promotes esophageal squamous cell carcinoma progression by targeting FOXA3 and indicates poor survival outcome[J]. Heliyon, 2023, 9(10): e21056. DOI: 10.1016/j.heliyon.2023.e21056.
[9]	Suo D, Wang Z, Li L, et al. HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis[J]. Oncogene, 2020, 39(32): 5441-5454. DOI: 10.1038/s41388-020-1375-4. pmid: 32587398
[10]	Xi Y, Lin Y, Guo W, et al. Multi-omic characterization of genome-wide abnormal DNA methylation reveals diagnostic and prognostic markers for esophageal squamous-cell carcinoma[J]. Signal Transduct Target Ther, 2022, 7(1): 53. DOI: 10.1038/s41392-022-00873-8.
[11]	Yu Q, Xia N, Zhao Y, et al. Genome-wide methylation profiling identify hypermethylated HOXL subclass genes as potential markers for esophageal squamous cell carcinoma detection[J]. BMC Med Genomics, 2022, 15(1): 247. DOI: 10.1186/s12920-022-01401-x. pmid: 36447287
[12]	Su J, Huang YH, Cui X, et al. Homeobox oncogene activation by pan-cancer DNA hypermethylation[J]. Genome Biol, 2018, 19(1): 108. DOI: 10.1186/s13059-018-1492-3. pmid: 30097071
[13]	张丽媛, 郭舒静. 胃癌组织中HOXC10表达与临床病理特征的关系分析[J]. 临床医学工程, 2023, 30(7): 1015-1016. DOI: 10.3969/j.issn.1674-4659.2023.07.1015.
[14]	Yao S, He L, Zhang Y, et al. HOXC10 promotes gastric cancer cell invasion and migration via regulation of the NF-κB pathway[J]. Biochem Biophys Res Commun, 2018, 501(3): 628-635. DOI: 10.1016/j.bbrc.2018.05.019.
[15]	Sandoval C, Nisson K, Fregoso OI. HIV-1 Vpr-induced DNA damage activates NF-κB through ATM-NEMO independent of cell cycle arrest[J]. mBio, 2024, 15(10): e0024024. DOI: 10.1128/mbio.00240-24.
[16]	Li J, Tong G, Huang C, et al. HOXC10 promotes cell migration, invasion, and tumor growth in gastric carcinoma cells through upregulating proinflammatory cytokines[J]. J Cell Physiol, 2020, 235(4): 3579-3591. DOI: 10.1002/jcp.29246. pmid: 31552684
[17]	Lin ZH, He JM, Lai SC, et al. HOXC10 indicates poor survival outcome in gastric cancer and promotes G₁/S cell cycle transition through transcriptional repression of p21[J]. Neoplasma, 2022, 69(6): 1303-1313. DOI: 10.4149/neo_2022_220609N615.
[18]	Kim J, Bae DH, Kim JH, et al. HOXC10 overexpression promotes cell proliferation and migration in gastric cancer[J]. Oncol Rep, 2019, 42(1): 202-212. DOI: 10.3892/or.2019.7164. pmid: 31115563
[19]	Li J, Sun K, Zhang M, et al. Long non-coding RNA CYTOR enhances gastric carcinoma proliferation, migration and invasion via the miR-136-5p/HOXC10 axis[J]. Am J Cancer Res, 2023, 13(6): 2714-2731.
[20]	He J, Ge Q, Lin Z, et al. MiR-129-5p induces cell cycle arrest through modulating HOXC10/Cyclin D1 to inhibit gastric cancer progression[J]. FASEB J, 2020, 34(6): 8544-8557. DOI: 10.1096/fj.201903217R. pmid: 32356314
[21]	Yu J, Zhang X, Ma Y, et al. MiR-129-5p restrains apatinib resistance in human gastric cancer cells via downregulating HOXC10[J]. Cancer Biother Radiopharm, 2021, 36(1): 95-105. DOI: 10.1089/cbr.2019.3107.
[22]	Dang Y, Chen J, Feng W, et al. Interleukin 1β-mediated HOXC10 overexpression promotes hepatocellular carcinoma metastasis by upregulating PDPK1 and VASP[J]. Theranostics, 2020, 10(8): 3833-3848. DOI: 10.7150/thno.41712. pmid: 32206125
[23]	Li M, Guo Q, Shi Q, et al. m⁶A-mediated upregulation of HOXC10 promotes human hepatocellular carcinoma development through PTEN/AKT/mTOR signaling pathway[J]. Horm Cancer, 2023, 14(1): 175. DOI: 10.1007/s12672-023-00786-0.
[24]	Enteghami M, Ghorbani M, Zamani M, et al. HOXC10 is significantly overexpressed in colorectal cancer[J]. Biomed Rep, 2020, 13(3): 18. DOI: 10.3892/br.2020.1325. pmid: 32765857
[25]	Xie Y, Chen R, Yan L, et al. Transcription factor HOXC10 activates the expression of MTFR2 to regulate the proliferation, invasion and migration of colorectal cancer cells[J]. Mol Med Rep, 2021, 24(5): 797. DOI: 10.3892/mmr.2021.12437.
[26]	Yu J, Chen X, Zhao S, et al. HOXC10 promotes metastasis in colorectal cancer by recruiting myeloid-derived suppressor cells[J]. J Cancer, 2022, 13(12): 3308-3317. DOI: 10.7150/jca.76945. pmid: 36186898
[27]	Sieminska I, Baran J. Myeloid-derived suppressor cells in colorectal cancer[J]. Front Immunol, 2020, 11: 1526. DOI: 10.3389/fimmu.2020.01526. pmid: 32849517
[28]	Chen Z, Wu J, Liu B, et al. Identification of cis-HOX-HOXC10 axis as a therapeutic target for colorectal tumor-initiating cells without APC mutations[J]. Cell Rep, 2021, 36(4): 109431. DOI: 10.1016/j.celrep.2021.109431.

HOXC10在消化系统肿瘤中的研究进展

Research progress of HOXC10 in digestive system neoplasms

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴市委, 裴康佳, 张东星, 秦占雨, 郭树霞. EVI1在急性髓系白血病中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 474-477.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王莉, 肖翰, 黄国福. 环状RNA在三阴性乳腺癌中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2024, 51(12): 774-778.
[4]	叶彤彤, 吴泽宇, 席文一, 王芝微, 江晓春, 赵晨辉. ABRACL在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2023, 50(9): 544-547.
[5]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[6]	徐凯, 文刚, 李瑞, 田园. 淋巴细胞与C反应蛋白比值对消化系统肿瘤预后价值的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 627-629.
[7]	张静, 黄守国, 夏鹰. CeRNA网络介导恶性肿瘤表型调控的机制研究[J]. 国际肿瘤学杂志, 2021, 48(9): 544-548.
[8]	居欣月, 胡春梅, 赵月, 唐艳. CDX2与胃肠道肿瘤[J]. 国际肿瘤学杂志, 2021, 48(6): 374-376.
[9]	刘培培, 杨梦雪, 严雪冰. m⁶A甲基化修饰在消化系统肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(11): 688-692.
[10]	任梦, 高燕, 陈琪, 岳文涛. 角蛋白在肿瘤诊断及预后中的应用[J]. 国际肿瘤学杂志, 2020, 47(6): 360-363.
[11]	赵聪选, 于韬. 胶质瘤相关基因的挖掘及预测[J]. 国际肿瘤学杂志, 2020, 47(5): 293-296.
[12]	马英骥, 孙丽斌, 邱文生. 长非编码RNA GHET1在消化系统肿瘤中的作用机制[J]. 国际肿瘤学杂志, 2020, 47(5): 304-307.
[13]	朱泽民, 谢智钦, 孙永康, 唐才喜. 微小RNA-223与消化系统肿瘤[J]. 国际肿瘤学杂志, 2020, 47(2): 112-114.
[14]	王昭,王迎难,倪吉祥,朱晶. Hippo信号通路及其在非小细胞肺癌中的表达和作用[J]. 国际肿瘤学杂志, 2019, 46(4): 239-242.
[15]	齐瑞丽, 王华庆. 血管靶向药物联合PD-1/PD-L1抗体在消化系统肿瘤治疗中的研究进展[J]. 国际肿瘤学杂志, 2019, 46(12): 750-754.